Dept. of Chemistry and Biochemistry Seminar
- Friday, September 17, 2021 at 3:10pm
- Chemistry & Biochemistry Bldg, Byker Auditorium - view map
Dr. Paul Galatsis (Vibliome Therapeutics, Bozeman, MT) will present "Discovery and Preclinical Profiling of LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease."
Parkinson’s disease (PD) is the most prevalent movement disorder and second most common neurodegenerative disease. Genome-wide association studies (GWAS) have confirmed that leucine-rich repeat kinase 2 (LRRK2) gain of function mutations represent the most common cause of familial PD. This presentation will illustrate how medicinal chemistry enabled a greater understanding of the LRRK2 biology associated with PD by discussing the identification, optimization, and preclinical profiling of potent, orally active, and brain penetrant LRRK2 inhibitors.
Host: Dr. Garrett Moraksi
Join us in the Byker Auditorium or by WEBEX
- Department of Chemistry and Biochemistry